XML 79 R73.htm IDEA: XBRL DOCUMENT
v3.25.3

Segments - Schedule of Revenues by Major Products and Activities (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | $ 4,480 |  | $ 4,332 |  | $ 12,547 |  | $ 12,315 |
United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 2,483 |  | 2,225 |  | 6,543 |  | 6,060 |
Europe [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 1,235 |  | 1,265 |  | 3,726 |  | 3,749 |
International Markets [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 557 |  | 613 |  | 1,634 |  | 1,802 |
Generic products (including OTC and biosimilars) [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 1,175 |  | 1,094 |  | 2,984 |  | 2,924 |
Generic products (including OTC and biosimilars) [Member] | Europe [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 982 |  | 973 |  | 3,011 |  | 2,947 |
Generic products (including OTC and biosimilars) [Member] | International Markets [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 421 |  | 477 |  | 1,298 |  | 1,440 |
AJOVY [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 73 |  | 58 |  | 190 |  | 144 |
AJOVY [Member] | Europe [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 66 |  | 56 |  | 195 |  | 158 |
AJOVY [Member] | International Markets [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 30 |  | 24 |  | 78 |  | 63 |
AUSTEDO [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 601 |  | 435 |  | 1,492 |  | 1,124 |
AUSTEDO [Member] | International Markets [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 17 |  | 13 |  | 34 |  | 39 |
BENDEKA and TREANDA [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 35 |  | 40 |  | 111 |  | 127 |
COPAXONE [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 62 |  | 69 |  | 179 |  | 179 |
COPAXONE [Member] | Europe [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 44 |  | 53 |  | 135 |  | 163 |
COPAXONE [Member] | International Markets [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 8 |  | 13 |  | 25 |  | 38 |
UZEDY [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 43 |  | 35 |  | 136 |  | 75 |
Anda [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 392 |  | 380 |  | 1,130 |  | 1,134 |
Respiratory Product [Member] | Europe [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 52 |  | 60 |  | 162 |  | 183 |
Other [Member] | United States [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 101 |  | 115 |  | 321 |  | 352 |
Other [Member] | Europe [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | 91 | [1] | 124 | [1] | 223 | [2] | 299 | [2]
Other [Member] | International Markets [Member] |  |  |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |  |  |
Revenues | $ 82 | [1] | $ 86 | [1] | $ 199 | [2] | $ 222 | [2]
[1] | Other revenues in the third quarter of 2025 and 2024 include the sale of certain product rights.
[2] | Other revenues in the first nine months of 2025 and 2024 include the sale of certain product rights.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_UnitedStatesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_EuropeSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=teva_InternationalMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_GenericsMediciansIncludingOtcAndBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AjovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AustedoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_BendekaAndTreandaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_COPAXONEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_UzedyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_AndaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_RespiratoryProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |